Reimagining Medicine slide image

Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology Ophthalmology Other Conclusions Neuroscience Global Health Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 78 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation